NCT06692881Completed
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
Evaluation of Function And Satisfaction of UbrogepanT-treated Migraine Patients in Canada (FAST): Prospective, Observational, Real-world Study
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate function and satisfaction with oral ubrogepant in treating adult participants after multiple migraine attacks. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Approximately 167 participants will be enrolled in approximately 10-15 sites across Canada. Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 12 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 178 (actual)
- First submitted
- 15 Nov 2024
- Start date
- 12 Feb 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- AbbVie
- Diseases
- Migraine
- NCT number
- NCT06692881
What you commit to
- Study type: Observational
- Participants enrolled: 178
- From 12 Feb 2025 to the primary completion date, 1 Jun 2026
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants previously exposed to a ubrogepant or rimegepant as routine therapy or through a clinical trial.
Other illness
- Participants with history of known contraindications to ubrogepant as per local labeling.
- History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.
Other
- Participants Pregnant or planning to be pregnant or of childbearing potential not using contraception
- Participants enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies.
Who the study is looking for
- Participants able to give voluntary informed consent before starting any study-related assessments or procedures (to be obtained/documented as per local regulations).
- Adults (≥18 years of age) at time of informed consent.
- Participants with at least 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (2018).
- Participants with history of experiencing at least 3 migraine attacks per month with moderate to severe symptoms
- Participants prescribed ubrogepant by investigator for the acute treatment of migraine according to local product label, independent of and prior to study participation
- Participants willing and able to comply with the requirements of the study.
- Participants with access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Calgary Headache Assessment and Management Program /ID# 271475 Coordinator of this site? Confirm its status | Calgary | Canada | Unknown status |
| Maritime Neurology /ID# 271867 Coordinator of this site? Confirm its status | Halifax | Canada | Unknown status |
| Neurocentre of Eastern Ontario /ID# 271865 Coordinator of this site? Confirm its status | Kingston | Canada | Unknown status |
| Centre de Recherche St-Louis /ID# 272843 Coordinator of this site? Confirm its status | Lévis | Canada | Unknown status |
| London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 272031 Coordinator of this site? Confirm its status | London | Canada | Unknown status |
| Centricity /ID# 271477 Coordinator of this site? Confirm its status | London | Canada | Unknown status |
| Genge Partners /ID# 273302 Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| Bayshore Neurology /ID# 280213 Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
| 360 Concussion Care /ID# 271972 Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
| Diex Recherche Sherbrooke /ID# 271677 Coordinator of this site? Confirm its status | Sherbrooke | Canada | Unknown status |
| Sunnybrook Health Sciences Centre /ID# 276844 Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| Burrard Health Center /ID# 271474 Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
| Royal Jubilee Hospital /ID# 271476 Coordinator of this site? Confirm its status | Victoria | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.